Search Results

US-based NuCube Launches High-Temperature Testing of 250 kW Pump-Free Microreactor in Utah

Advanced nuclear developer NuCube Energy is conducting a new round of non-nuclear testing in Utah, USA, on its factory-assembled microreactor technology. The company is collaborating with researchers from Brigham Young University to advance the project at the San Rafael Energy Research Laboratory. The partners are using electric heating technology to precisely simulate the operating conditions inside their planned NuSun micro fission system. The core focus of this round of testing is to verify whether small modular nuclear energy can provide clean, decarbonized energy support for high-energy-consumption manufacturing operations. Conventional commercial nuclear power plants typically rely on mechanical pumps and large pools to manage core temperature. Once mechanical components fail or...

2026-10-10

Alpha-9 Oncology Initiates Phase 1 Clinical Trial of GRPR-Targeted Radiotherapy, First Patient Dosed

Alpha-9 Oncology, a U.S. clinical-stage radiopharmaceutical company, recently announced that the first patient has been dosed in its Phase 1 clinical trial evaluating two GRPR-targeted radiopharmaceuticals. The study involves the actinium-225-labeled compound 225Ac-A9-0642 and the lutetium-177-labeled compound 177Lu-A9-0631, primarily enrolling patients with breast cancer and other solid tumors, with data expected to be released by the end of 2027. According to the company, both 225Ac-A9-0642 and 177Lu-A9-0631 target the gastrin-releasing peptide receptor (GRPR). GRPR is considered a solid tumor-associated target with potential clinical value in breast cancer and other solid tumors. 225Ac-A9-0642 is Alpha-9's first actinium-225 GRPR-targeted compound to enter clinical evaluation...

2026-09-09

Global nuclear power generation hits record high in 2025

According to the World Nuclear Outlook Report released by the World Nuclear Association (WNA), global electricity generation from nuclear reactors reached 2,702 TWh in 2025, up from 2,667 TWh in 2024, setting a new historical record. The report estimates that if all countries' stated nuclear energy targets are fully achieved, global nuclear installed capacity could more than triple current levels by 2050. The report assesses the progress made by 38 countries toward the goal of tripling global nuclear capacity by 2050, and puts forward policy recommendations for governments, industry, financial institutions, and regulators. In terms of operating nuclear units, the report notes that despite the increasing service life of individual units, global nuclear power plants...

2026-09-08

World's First 250,000 Tonne-Meter Ring Crane Rolls Off Production Line, Supporting Hualong One 2.0 Nuclear Power Construction

On August 31, the world's first 250,000 tonne-meter ring crane, jointly developed by SANY Heavy Lift and China Energy Engineering Group Guangdong Thermal Power & Litte Company, rolled off the production line at SANY's Huzhou Industrial Park in Zhejiang. Designed for the "one crane, two islands" construction requirements of Hualong One 2.0, the equipment can address the engineering challenge of covering module hoisting for two nuclear islands with a single unit, marking a key domestic localization breakthrough in China's ultra-large-tonnage nuclear power hoisting equipment. With the advancement of the Hualong One 2.0 "one crane, two islands" construction method, nuclear power projects have imposed higher requirements on the working radius, load capacity, and hoisting precision of heavy lifting equipment. In the past, related high-end equipment technology was long controlled by a few overseas companies. The 250,000 tonne-meter ring crane rolled off the production line this time has undergone seven years of technical research, achieving breakthroughs in structural design, manufacturing processes, and assembly control.

2026-09-02

Balakovo NPP Publishes 2025 Ecological Safety Report

Russia's Balakovo NPP released its 2025 ecological safety report on August 31, 2026. The report data show that the plant's operational activities comply with the requirements of sanitary, epidemiological, and environmental protection regulations. The report was presented in a roundtable format. Participants learned about the plant's ecological policy and the results of environmental monitoring studies, and exchanged views on relevant issues. Alexander Kurlov, head of the external radiation safety laboratory at Balakovo NPP, stated that before the plant's construction, the natural gamma background of the local area had to be measured and its upper and lower limits determined. Since the plant was put into operation, no exceedances of these limits have been recorded at the industrial site or in the surrounding areas.

2026-09-01

Defence Therapeutics Expands Radiopharmaceutical R&D Program to Evaluate Alpha and Beta Emitter Applications

MONTREAL, Quebec, Canada — Biotechnology company Defence Therapeutics Inc. recently announced the expansion of its radiopharmaceutical R&D program to include α and β radioisotopes in its evaluation scope, further validating the application potential of its proprietary Accum® technology in precision oncology. Defence Therapeutics is a publicly traded biotechnology company developing next-generation oncology treatments centered on its Accum® precision drug delivery platform. The company stated that the Accum® technology is designed to facilitate the entry of drug payloads into the intracellular compartment, thereby improving delivery efficiency. This expansion of the radiopharmaceutical program...

2026-09-01

Finland's 2025 Environmental Radiation Monitoring Shows No Harmful Effects from Nuclear Power Plant Operations

The 2025 environmental radiation monitoring results released recently by the Radiation and Nuclear Safety Authority of Finland (STUK) show that radioactive substance levels in the Finnish environment generally remained low, and the operation of the Loviisa and Olkiluoto nuclear power plants has not caused harmful radiation impacts on the public or the environment. STUK continuously tracks Finland's radiation situation through its environmental radiation monitoring program. The monitoring includes continuous measurement of external radiation, as well as monitoring of radioactive substances in air, radioactive fallout, water bodies, food, and the human body, with the aim of promptly detecting changes in radiation levels and confirming the safety of the living environment. Finland's automatic external radiation monitoring network covers essentially the entire country. In 2025, 255 monitoring...

2026-08-31

Russia Deepens Nuclear Power Plant Construction Cooperation in Asia and Africa in 2025

Rosatom recently released a report stating that in 2025, the company made progress in cooperation on the construction of large and small nuclear power plants in Asia and Africa, further consolidating its position as a global technology partner. The report noted that by the end of 2025, Rosatom's offerings to partner countries had expanded beyond the energy sector to encompass more comprehensive technological cooperation. Key achievements include advancing cooperation on large nuclear power plants and small modular reactor projects in Central Asia, Africa, and Southeast Asia, as well as expanding exports of non-energy products. In the non-energy sector, the report mentioned that Rosatom has opened an additive manufacturing center in Belarus and plans to...

2026-08-30

Bristol Myers Squibb to Invest $173 Million in New Radiopharmaceutical Plant in Indiana, USA

Bristol Myers Squibb's RayzeBio will build a new radiopharmaceutical production facility in Whitestown, Indiana, USA, with an investment of $173 million. The project will be located at the Anson Industrial Park in Boone County, with construction planned to begin this year, complementing RayzeBio's existing operational radiopharmaceutical plant in Indianapolis. According to information released by the state of Indiana, the new facility will cover approximately 225,000 square feet. Bristol Myers Squibb expects the two production sites to add 100 new positions by the end of 2029, with annual salaries for new positions expected to exceed $130,000. Bristol Myers Squibb acquired San Diego-based RayzeBio in 2023 for $4.1 billion...

2026-08-28

New Analytical Laboratory Completed at Oak Ridge to Support U-233 Cleanup and Medical Isotope Supply

The U.S. Department of Energy Oak Ridge Environmental Management Office (OREM) and its contractor Isotek Systems completed installation of a new analytical laboratory at Oak Ridge National Laboratory (ORNL) on August 25, 2026. The laboratory will support ORNL's highest-priority environmental cleanup project and accelerate delivery of critical medical isotope materials for cancer treatment research. Isotek Systems is responsible for removing the U.S. uranium-233 inventory stored at Oak Ridge National Laboratory. Uranium-233 was primarily developed in the 1950s and 1960s, initially intended for use as nuclear reactor fuel, but was later proven unsuitable as a commercial fuel source...

2026-08-26

Two production lines at radiopharmaceutical plant in Russia's Kaluga Region enter trial production

Rosatom recently announced that two production lines at its modern radiopharmaceutical manufacturing facility in the Kaluga Region have entered trial production. The facility, built in accordance with the Eurasian Economic Union's international Good Manufacturing Practice (GMP) standards, is equipped with high-level production equipment and is designed to supply safe, quality-controlled radiopharmaceuticals to the market. According to reports, Rosatom's subsidiary enterprises currently produce more than ten registered diagnostic and therapeutic radiopharmaceuticals, involving isotopes such as iodine-123, iodine-131, technetium-99m, and samarium-153. The new plant's production plan is based on the demand for radioisotope products from Russian medical institutions through 2030. The company...

2026-08-26

Kyoto Fusioneering Completes 25.72 Billion Yen Series D Funding Round

Japanese fusion startup Kyoto Fusioneering announced on August 24 that it has completed the first closing of its Series D funding round, with total financing of 25.72 billion yen. Of this amount, equity financing totaled 16.72 billion yen and debt financing totaled 9 billion yen, with the debt portion comprising credit lines and loan facilities. With this, the company's cumulative equity financing has reached 32.98 billion yen. Following this funding round, Kyoto Fusioneering is valued at approximately 120 billion yen, a significant increase from its pre-funding valuation, making it the first startup in Japan's fusion sector to exceed a valuation of 100 billion yen. The company has previously secured contracts exceeding 14 billion yen cumulatively in markets such as North America and Europe, and has set a short-term sales target of approximately 10 billion yen.

2026-08-24

Russia's Novovoronezh NPP Publishes 2025 Environmental Safety Report

Russia's Novovoronezh Nuclear Power Plant recently released its 2025 environmental safety report to the public. The presentation of the report was arranged during navigation activities on the Don River, with participation from plant representatives, representatives of the Russian Ecological Society, personnel from relevant public institutions of Voronezh Oblast, environmental experts, journalists, and bloggers. The report focuses on the plant's impact on the surrounding environment and monitoring activities. According to Novovoronezh NPP, the plant conducts monthly water quality inspections at 24 control points along the Don River, most of which are located within urban areas. During the event, staff also demonstrated the water sampling process from the Don River at the plant's dedicated pier...

2026-08-23

SuperMag New Energy Achieves Milestone Progress in Development of 25 T-Class High-Temperature Superconducting Toroidal Field Model Magnet

Recently, SuperMag New Energy has achieved two milestone progresses in the development of its 25 T-class high-temperature superconducting toroidal field model magnet: following the completion of R&D and testing of the first panel-type high-temperature superconducting single pancake coil, the company has initiated batch manufacturing of panel-type single pancake coils; meanwhile, the self-developed 24 cm² low-resistance detachable joint has completed prototype fabrication and performance testing in the liquid nitrogen temperature range, with an equivalent joint resistance of approximately 33 nΩ. These two progresses correspond to two critical aspects: stable manufacturing of single pancake coils and low-loss interconnection of multiple units. The project has advanced from the single-component process validation stage toward multi-pancake manufacturing and model magnet system integration. The single pancake coil is not an ordinary component in the model magnet, but rather a fundamental unit integrating conductor, panel structure, insulation, electrical connection, and testing interfaces. Each single pancake requires independent manufacturing and inspection, and also serves as the foundation for subsequent multi-pancake stacking, magnet excitation, and cryogenic operation.

2026-08-21

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20